Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs

被引:9
作者
Abraham, Amanda J. [1 ,2 ]
O'Brien, Lauren A. [1 ]
Knudsen, Hannah K. [3 ,4 ]
Bride, Brian E. [5 ]
Smith, G. Rush [1 ]
Roman, Paul M. [1 ,2 ]
机构
[1] Univ Georgia, Owens Inst Behav Res, Athens, GA 30602 USA
[2] Univ Georgia, Dept Sociol, Athens, GA 30602 USA
[3] Univ Kentucky, Dept Behav Sci, Lexington, KY 40506 USA
[4] Univ Kentucky, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA
[5] Univ Georgia, Sch Social Work, Athens, GA 30602 USA
关键词
HIV testing; Substance use disorders; Treatment programs; DRUG-ABUSE-TREATMENT; SEXUALLY-TRANSMITTED INFECTIONS; C VIRUS-INFECTION; HEPATITIS-C; ON-SITE; INNOVATION ADOPTION; HEALTH-SERVICES; PREVENTION; HIV/AIDS; RISK;
D O I
10.1016/j.jsat.2012.03.004
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Racial and ethnic minorities and injection drug users (IDUs) are at increased risk of HIV infection. However, the associations between these caseload characteristics and the availability of onsite HIV testing in substance use disorder treatment programs are unknown. This study uses data collected in 2008-2009 from 198 program administrators of treatment programs participating in the National Institute on Drug Abuse's Clinical Trials Network to address. this gap in the literature. Results show positive associations between the percentages of African American, Hispanic, and IDU patients and the odds of offering non-rapid onsite HIV testing versus no onsite testing. The associations between racial/ethnic composition and the availability of rapid HIV testing were more complicated. These findings suggest that many programs are responding to the needs of at-risk populations. However, programs and their patients may benefit from greater adoption of rapid testing which is less costly and better ensures that patients receive their results. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:120 / 125
页数:6
相关论文
共 62 条
  • [11] A tale of two futures: HIV and antiretroviral therapy in San Francisco
    Blower, SM
    Gershengorn, HB
    Grant, RM
    [J]. SCIENCE, 2000, 287 (5453) : 650 - 654
  • [12] Branson B. M., 2000, AIDS REV, V20, P76
  • [13] Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
  • [14] Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: The National Drug Abuse Treatment Clinical Trials Network
    Brown, Lawrence S., Jr.
    Kritz, Steven Allan
    Goldsmith, R. Jeffrey
    Bini, Edmund J.
    Rotrosen, John
    Baker, Sherryl
    Robinson, Jim
    McAuliffe, Patrick
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2006, 30 (04) : 315 - 321
  • [15] Centers for Disease Control and Prevention, 2007, EXP INT HUM IMM VIR
  • [16] Centers for Disease Control and Prevention, 2009, HIV TEST AD
  • [17] Centers for Disease Control and Prevention, 2006, HIV COUNS TEST CDC S
  • [18] Centers for Disease Control and Prevention, 2002, MMWR WEEKL UPD AIDS
  • [19] Colfax GN, 2001, J ACQ IMMUN DEF SYND, V28, P373, DOI 10.1097/00126334-200112010-00011
  • [20] An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units
    D'Aunno, T
    Vaughn, TE
    McElroy, P
    [J]. JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1999, 40 (02) : 175 - 192